Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00040820
Status:
COMPLETED
Last Update Posted:
2011-03-07
First Post:
2002-07-08
Brief Title:
Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Study Overview
Official Title:
A Treatment Access Program With Oxaliplatin for Previously Treated Colorectal Cancer Patients
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Clinical trial to study the effectiveness of oxaliplatin in treating patients who have locally advanced or metastatic colorectal cancer that has been previously treated
PURPOSE Clinical trial to study the effectiveness of oxaliplatin in treating patients who have locally advanced or metastatic colorectal cancer that has been previously treated
Detailed Description:
OBJECTIVES
Provide oxaliplatin for patients with previously treated locally advanced or metastatic colorectal cancer who have exhausted all approved therapies for colorectal cancer
OUTLINE This is a multicenter Treatment Access Program study
Patients receive oxaliplatin IV over 2 hours on day 1 Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity
Patients are followed for at least 30 days
PROJECTED ACCRUAL Approximately one patient per site per month will be accrued for this study
Provide oxaliplatin for patients with previously treated locally advanced or metastatic colorectal cancer who have exhausted all approved therapies for colorectal cancer
OUTLINE This is a multicenter Treatment Access Program study
Patients receive oxaliplatin IV over 2 hours on day 1 Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity
Patients are followed for at least 30 days
PROJECTED ACCRUAL Approximately one patient per site per month will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RPCI-DS-0130 | None | None | None |